Rapport Therapeutics Inc [RAPP] stock is trading at $28.03, down -10.93%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RAPP shares have gain 71.23% over the last week, with a monthly amount glided 92.65%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rapport Therapeutics Inc [NASDAQ: RAPP] stock has seen the most recent analyst activity on August 06, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $31. On July 02, 2024, TD Cowen initiated with a Buy rating. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $35 on July 02, 2024. Jefferies initiated its recommendation with a Buy and recommended $35 as its price target on July 02, 2024.
Rapport Therapeutics Inc [RAPP] stock has fluctuated between $6.43 and $42.27 over the past year. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Rapport Therapeutics Inc [NASDAQ: RAPP] shares were valued at $28.03 at the most recent close of the market. An investor can expect a potential return of 24.87% based on the average RAPP price forecast.
Analyzing the RAPP fundamentals
Gross Profit Margin for this corporation currently stands at -0.49% with Operating Profit Margin at -141.34%, Pretax Profit Margin comes in at -122.66%, and Net Profit Margin reading is -122.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.3 and Total Capital is -0.37. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.89 points at the first support level, and at 23.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.59, and for the 2nd resistance point, it is at 35.14.
Ratios To Look Out For
For context, Rapport Therapeutics Inc’s Current Ratio is 22.75. In addition, the Quick Ratio stands at 22.75 and the Cash Ratio stands at 4.64.
Transactions by insiders
Recent insider trading involved CHERYL GAULT, Officer, that happened on Sep 08 ’25 when 10000.0 shares were purchased. Chief Scientific Officer, Bredt David completed a deal on Aug 15 ’25 to sell 8500.0 shares. Meanwhile, Chief Scientific Officer Bredt David sold 8500.0 shares on Jul 15 ’25.
